- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation | 198 | ACCESS Newswire | Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the... ► Artikel lesen | |
| ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 18.06. | Aspire Biopharma Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Michael Howe takes helm as CEO of Aspire Biopharma | 2 | Investing.com | ||
| 10.06. | Michael Howe übernimmt die Leitung als CEO von Aspire Biopharma | 1 | Investing.com Deutsch | ||
| 10.06. | Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer | 233 | ACCESS Newswire | Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo... ► Artikel lesen | |
| 10.06. | Aspire Biopharma Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB, its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025 | 359 | ACCESS Newswire | Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout marketInitial production has commenced with six flavor optionsExpanded... ► Artikel lesen | |
| 20.05. | Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation | 259 | ACCESS Newswire | Trial marks key milestone in driving pipeline progressPhase 1 trial scheduled for completion mid-June 2025Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support... ► Artikel lesen | |
| 14.05. | Aspire Biopharma Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Aspire Biopharma announces resale of up to 11.26M shares | 3 | Seeking Alpha | ||
| 13.05. | Aspire Biopharma Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 08.05. | Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21 | 195 | ACCESS Newswire | HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug... ► Artikel lesen | |
| 29.04. | Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation | 304 | ACCESS Newswire | Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or... ► Artikel lesen | |
| 18.04. | Aspire Biopharma Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.04. | Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17 | 259 | ACCESS Newswire | HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery... ► Artikel lesen | |
| 11.04. | Aspire Biopharma beginnt mit der Produktion von Pre-Workout-Nahrungsergänzungsmitteln | 2 | Investing.com Deutsch | ||
| 11.04. | Aspire Biopharma starts production of pre-workout supplement | 2 | Investing.com | ||
| 11.04. | Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement | 205 | ACCESS Newswire | Plans to conduct consumer and safety testing during second quarter 2025Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial productionSingle... ► Artikel lesen | |
| 09.04. | Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation | 275 | ACCESS Newswire | One clinical trial site activatedPatient enrollment expected in AprilTrial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin productAspire anticipates... ► Artikel lesen | |
| 09.04. | Aspire Biopharma Holdings, Inc. - S-1, General form for registration of securities | 4 | SEC Filings |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PROMINO NUTRITIONAL SCIENCES | 0,034 | -100,00 % | Promino Nutritional Sciences, Inc.: Promino Nutritional Sciences Inc. Comments on Trading Halt | Burlington, Ontario--(Newsfile Corp. - May 20, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the "Company" or "Promino") provides an update on the trading halt... ► Artikel lesen | |
| IMMUNOPRECISE ANTIBODIES | 0,995 | +5,29 % | ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer | ||
| BAYER | 26,975 | +2,64 % | DZ BANK stuft BAYER AG auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Aktien von Bayer bei einem fairen Wert von 36 Euro auf "Kaufen" belassen. Der Agrarchemie- und Pharmakonzern sei besser als erwartet ins Jahr gestartet... ► Artikel lesen | |
| MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
| NOVO NORDISK | 58,70 | +0,09 % | JPMORGAN stuft NOVO NORDISK auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Novo Nordisk nach Studiendaten zu Cagrisema auf "Overweight" mit einem Kursziel von 650 dänischen Kronen belassen. Der Markt... ► Artikel lesen | |
| PFIZER | 20,665 | +0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
| EYENOVIA | 10,960 | +38,91 % | Eyenovia launches validator node for Hyperliquid blockchain | ||
| ROCKET LAB | 30,200 | -0,10 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
| ASTRAZENECA | 120,05 | +0,42 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Die beschleunigte US-Zulassung von Datroway gegen... ► Artikel lesen | |
| DERMAPHARM | 34,750 | 0,00 % | EQS-DD: Dermapharm Holding SE: Dr. Andreas Eberhorn, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.06.2025 / 16:45... ► Artikel lesen | |
| ELI LILLY | 670,70 | -1,27 % | Eli Lilly and Company: Lilly declares third-quarter 2025 dividend | INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025... ► Artikel lesen | |
| SANOFI | 82,30 | +0,01 % | Minimale Kursveränderung bei Sanofi SA-Aktie (82,73 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Sanofi SA . Das Wertpapier notiert aktuell bei 82,73 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem Anteilsschein von... ► Artikel lesen | |
| ALTIMMUNE | 2,951 | -0,87 % | Altimmune, Inc: Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH | First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis... ► Artikel lesen | |
| GSK | 16,510 | +0,24 % | GSK's Benlysta Autoinjector Gets FDA Approval For Children With Active Lupus Nephritis | LONDON (dpa-AFX) - GSK plc (GSK.L) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved Benlysta autoinjector for individuals aged five years and older with active lupus... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 14,030 | +0,50 % | Eton Pharmaceuticals to join Russell indexes |
Das Unternehmen ASPIRE BIOPHARMA HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,014 (+4,54 %) liegt der Kurs bei 0,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASPIRE BIOPHARMA HOLDINGS INC finden Sie auf Wallstreet Online.